Acrodermatitis chronica atrophicans: Difference between revisions
No edit summary |
|||
| Line 12: | Line 12: | ||
| MeshID = | | MeshID = | ||
}} | }} | ||
{{ | {{ACA}} | ||
{{CMG}}; {{AE}} {{RT}} | {{CMG}}; {{AE}} {{RT}} | ||
Revision as of 14:35, 31 October 2012
| Acrodermatitis chronica atrophicans | |
| ICD-10 | L90.4 |
|---|---|
| ICD-9 | 701.8 |
| DiseasesDB | 32940 |
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans |
|
Risk calculators and risk factors for Acrodermatitis chronica atrophicans |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Synonyms and keywords: Pick-Herxheimer disease; ACA
Overview
Acrodermatitis chronica atrophicans is a skin rash indicative of the third or late stage of European Lyme borreliosis.
ACA is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.
Historical Perspective
- The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.
- Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.
Pathophysiology
- This progressive skin process is due to the effect of continuing active infection with the spirochete Borrelia afzelii. B afzelii is the predominant pathophysiology, but may not be the exclusive, etiologic agent of ACA. Borrelia garinii, has also been detected.
Microscopic Pathology
- Light and electron microscopic study of the skin biopsy shows degeneration of the elastica and collagen fibers.[1]
Natural History, Complications and Prognosis
- The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.
- The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.
Diagnosis
History
- A history of a recent tick bite should be inquired about.
Symptoms
- The rash caused by ACA is most evident on the extremities or limbs beginning with an inflammatory stage with bluish red discoloration and cutaneous swelling and concluding several months or years later with an atrophic phase. Sclerotic skin plaques may also develop.
- As ACA progresses the skin begins to wrinkle.
Laboratory Findings
- Physicians should use serologic and histologic examination to confirm the diagnosis of ACA.
- Biopsy shows chronic inflammatory signs in long standing cases. [2]
Treatment
- Treatment consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.
See also
References
- ↑ de Koning J, Tazelaar DJ, Hoogkamp-Korstanje JA, Elema JD (1995). "Acrodermatitis chronica atrophicans: a light and electron microscopic study". J. Cutan. Pathol. 22 (1): 23–32. PMID 7751475. Unknown parameter
|month=ignored (help) - ↑ Rosenlund S, Bækgaard N, Menné T (2011). "[Acrodermatitis chronica atrophicans can be difficult to diagnose]". Ugeskr. Laeg. (in Danish). 173 (50): 3272–3. PMID 22153213. Unknown parameter
|month=ignored (help)